Full Press Release Details
Iovance Biotherapeutics Initiates Biologics
License Application (BLA)
Submission for Lifileucel in Advanced Melanoma
First TIL Therapy BLA Submission Initiated
with U.S. Food and Drug Administration
Complete BLA Submission on Track for Fourth
SAN CARLOS, Calif., August 25, 2022 -- Iovance
Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today
announced that it has initiated a rolling Biologics License Application (BLA) submission to the U.S. Food and Drug Administration (FDA)
for lifileucel, a tumor infiltrating lymphocyte (TIL) therapy, in patients with advanced (unresectable or metastatic) melanoma who progressed
on or after prior anti-PD-1/L1 therapy, and if BRAF mutation positive, also prior BRAF or BRAF/MEK inhibitor therapy. There are no FDA
approved therapies in this treatment setting.
Frederick Vogt, Ph.D., J.D., Interim President and Chief Executive
Officer of Iovance, stated, "Initiating our rolling BLA submission for lifileucel is a significant step towards our goal to deliver
the first individualized, one-time cell therapy for melanoma patients with significant unmet need. In parallel, we are executing our
on-boarding and personnel training at authorized treatment centers, education and awareness initiatives, internal capacity planning,
and launch readiness activities to prepare for commercialization. The FDA is supportive of our regulatory approach, and we look forward
to continuing this collaboration throughout the submission and review process."
A rolling BLA allows Iovance to submit
portions of the BLA to the FDA on an ongoing basis, which enables the FDA to begin review as early as possible while documents are received.
Iovance expects to complete the BLA submission in the fourth quarter of 2022. The rolling BLA submission and eligibility for priority
review are benefits available under the FDA's guidance on expedited programs for serious conditions. The FDA previously
granted a regenerative medicine advanced therapy (RMAT) designation for lifileucel in advanced melanoma.
"Lifileucel represents hope and
a new treatment for thousands of people with advanced melanoma who have very limited options after they progress on available standard
of care," said Kyleigh LiPira, CEO, Melanoma Research Foundation. "Cell immunotherapies are revolutionizing cancer treatment,
and we are excited about the potential for the first FDA-approved TIL cell therapy for the treatment of melanoma, which helps
us take another step towards finding a cure."
The BLA submission for lifileucel is
supported by positive clinical data from the C-144-01 clinical trial in patients with advanced melanoma. Iovance plans
to present additional results from the C-144-01 trial at a medical meeting later this year.
About Iovance Biotherapeutics, Inc.
Iovance Biotherapeutics
aims to be the global leader in innovating, developing and delivering tumor infiltrating lymphocyte (TIL) therapies for patients with
cancer. We are pioneering a transformational approach to cure cancer by harnessing the human immune system's ability to recognize
and destroy diverse cancer cells in each patient. Our lead late-stage TIL product candidate, lifileucel for metastatic melanoma, has
the potential to become the first approved one-time cell therapy for a solid tumor cancer. The Iovance TIL platform has demonstrated
promising clinical data across multiple solid tumors. We are committed to continuous innovation in cell therapy, including gene-edited
cell therapy, that may extend and improve life for patients with cancer. For more information, please visit www.iovance.com.
Forward-Looking Statements
Certain matters discussed in this press release
are "forward-looking statements" of Iovance Biotherapeutics, Inc. (hereinafter referred to as the "Company,"
"we," "us," or "our") within the meaning of the Private Securities Litigation Reform Act of 1995
(the "PSLRA"). All such written or oral statements made in this press release, other than statements of historical fact,
are forward-looking statements and are intended to be covered by the safe harbor for forward-looking statements provided by the PSLRA.
Without limiting the foregoing, we may, in some cases, use terms such as "predicts," "believes," "potential,"
"continue," "estimates," "anticipates," "expects," "plans," "intends,"
"forecast," "guidance," "outlook," "may," "could," "might," "will,"
"should" or other words that convey uncertainty of future events or outcomes and are intended to identify forward-looking
statements. Forward-looking statements are based on assumptions and assessments made in light of management's experience and perception
of historical trends, current conditions, expected future developments and other factors believed to be appropriate. Forward-looking
statements in this press release are made as of the date of this press release, and we undertake no duty to update or revise any such
statements, whether as a result of new information, future events or otherwise. Forward-looking statements are not guarantees of future
performance and are subject to risks, uncertainties and other factors, many of which are outside of our control, that may cause actual
results, levels of activity, performance, achievements and developments to be materially different from those expressed in or implied
by these forward-looking statements. Important factors that could cause actual results, developments and business decisions to differ
materially from forward-looking statements are described in the sections titled "Risk Factors" in our filings with the Securities
and Exchange Commission, including our most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, and include, but are
not limited to, the following substantial known and unknown risks and uncertainties inherent in our business: the effects of the COVID-19
pandemic; risks related to the timing of and our ability to successfully develop, submit, obtain and maintain U.S. Food and Drug Administration
("FDA") or other regulatory authority approval of, or other action with respect to, our product candidates, and our ability
to successfully commercialize any product candidates for which we obtain FDA approval; whether clinical trial results from our pivotal
studies and cohorts may support registration and approval by the FDA; preliminary and interim clinical results, which may include efficacy
and safety results, from ongoing clinical trials or cohorts may not be reflected in the final analyses of our ongoing clinical trials
or subgroups within these trials or in other prior trials or cohorts; the risk that enrollment may need to be adjusted for our trials
and cohorts within those trials based on FDA and other regulatory agency input; the changing landscape of care for cervical cancer patients
may impact our clinical trials in this indication; the risk that we may be required to conduct additional clinical trials or modify ongoing
or future clinical trials based on feedback from the FDA or other regulatory authorities; the risk that our interpretation of the results
of our clinical trials or communications with the FDA may differ from the interpretation of such results or communications by the FDA
(including from the recent pre-BLA meeting with the FDA); the risk that the rolling BLA submission for lifileucel in metastatic melanoma
may take longer than expected; the acceptance by the market of our product candidates and their potential reimbursement by payors, if
approved; our ability or inability to manufacture our therapies using third party manufacturers or our own facility may adversely affect
our potential commercial launch; the results of clinical trials with collaborators using different manufacturing processes may not be
reflected in our sponsored trials; the risk that unanticipated expenses may decrease our estimated cash balances and forecasts and increase
our estimated capital requirements; and other factors, including general economic conditions and regulatory developments, not within
Iovance Biotherapeutics, Inc:
Sara Pellegrino, IRC
Senior Vice President, Investor Relations & Corporate Communications
650-260-7120 ext. 264
Director, Investor Relations & Public